Posted by Michael Wonder on 14 Jun 2022
Empagliflozin (Jardiance) approved by MHRA as UK’s first effective treatment for symptomatic chronic heart failure regardless of ejection fraction
14 June 2022 - The MHRA has granted marketing authorisation for the use of empagliflozin (Jardiance) as a treatment for adults with symptomatic chronic heart failure.
This breakthrough approval expands the existing indication of empagliflozin to include adults with heart failure with preserved ejection fraction, an underserved patient population who previously had no licensed and clinically proven therapies.
